Translate
About
Simcere Pharmaceutical Group Ltd (HK:2096) — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 27 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Nov 10 2025
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
Jun 19 2025
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
Financials
Revenue
HK$7.73 B
Market Cap
HK$35.18 B
P/E Ratio
22.33
EPS
0.36
Dividend Yield
1.33%